Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 18;15(6):539-551.
doi: 10.1002/cmdc.201900716. Epub 2020 Feb 17.

Design, Synthesis, and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors

Daniel A Rodrigues  1   2 , Fabiana S Guerra  3 , Fernanda S Sagrillo  1 , Pedro de Sena M Pinheiro  1   4 , Marina A Alves  5 , Sreekanth Thota  1 , Lorrane S Chaves  1   4 , Carlos M R Sant'Anna  1   6 , Patrícia D Fernandes  3 , Carlos A M Fraga  1   2   4
Affiliations

Design, Synthesis, and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors

Daniel A Rodrigues et al. ChemMedChem. .

Abstract

Targeting histone deacetylases (HDACs) and phosphatidylinositol 3-kinases (PI3Ks) is a very promising approach for cancer treatment. This manuscript describes the design, synthesis, in vitro pharmacological profile, and molecular modeling of a novel class of N-acylhydrazone (NAH) derivatives that act as HDAC6/8 and PI3Kα dual inhibitors. The surprising selectivity for PI3Kα may be related to differences in the conformation in the active site. Cellular studies showed that these compounds act in HDAC6 inhibition and the PI3/K/AKT/mTOR pathway. The compounds that are selective for inhibition of HDAC6/8 and inhibit PI3Kα show potential for the treatment of cancer.

Keywords: HDAC6; N-acylhydrazone; PI3Kα; cancer; multitarget inhibitors..

PubMed Disclaimer

References

    1. None
    1. J. E. Bolden, M. J. Peart, R. W. Johnstone, Nat. Rev. Drug Discovery 2006, 5, 769-784;
    1. K. J. Falkenberg, R. W. Johnstone, Nat. Rev. Drug Discovery 2014, 13, 673-691.
    1. O. Witt, H. E. Deubzer, T. Milde, I. Oehme, Cancer Lett. 2009, 277, 8-21.
    1. None

Publication types

MeSH terms

LinkOut - more resources